Exo Therapeutics, Inc. launched in December with $25m in series A venture capital and has advanced its ExoSight technology platform far enough since then to justify a $78m series B round that the company announced on 5 October. It plans to use the financing to advance initial drug candidates that target exosites – unique binding pockets that may be able to reprogram enzyme activity – towards the clinic. Exo will also continue to invest in the ExoSight platform.
“Exosites are found abundantly across the proteome, so part of the intent with this series B was to enable us to both expand our discovery efforts to purse novel exosite targets while not holding back on the